Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Medicenna Therapeutics Stock Up 4.1 %
Shares of Medicenna Therapeutics stock opened at C$2.27 on Tuesday. The stock's fifty day moving average is C$1.54 and its 200-day moving average is C$1.64. The firm has a market capitalization of C$127.81 million and a PE ratio of -4.82. The company has a quick ratio of 8.33, a current ratio of 8.92 and a debt-to-equity ratio of 0.06. Medicenna Therapeutics has a 12-month low of C$0.98 and a 12-month high of C$3.67.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a C$5.00 price objective on shares of Medicenna Therapeutics in a report on Thursday, June 23rd. Maxim Group assumed coverage on Medicenna Therapeutics in a report on Wednesday, June 22nd. They set a "buy" rating and a C$4.00 target price on the stock. Bloom Burton restated a "buy" rating and set a C$11.00 price objective on shares of Medicenna Therapeutics in a report on Thursday, July 28th. Finally, Brookline Capital Acquisition lifted their target price on Medicenna Therapeutics to C$14.00 and gave the stock a "buy" rating in a research report on Wednesday, April 13th.